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Abstract 
This chapter provides an overview of the varied definitions of New Psychoactive Substances 
(NPS) or so-called ‘legal highs’, along with data on (relatively low) prevalence in selected 
countries and user motivations in order to tease out the broader picture of what 
characterises NPS use. A new typology of NPS is proposed which couples pharmacological 
effects with chemical classifications, to provide an underlying framework for this review. 
The authors conclude that the dynamic interaction between the NPS market and policy 
change initially characterised as ‘cat and mouse’ might now be conceived of as ‘hare and 
hounds’ in that legislative control has been a significant driving force in manufacturing and 
retail innovations 
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Introduction 
One of the most interesting developments in the field of drug and alcohol studies in recent 
years has been the emergence of New Psychoactive Substances (NPS). This phenomenon is 
something of a (rapidly) moving target however, in terms of what we know about NPS, how 
different countries have reacted to their emergence and indeed, what we even mean by the 
term. This chapter will explore definitions, prevalence and user motivations in order to 
tease out the broader picture of what characterises NPS use, such that it should warrant a 
chapter in and of itself in this collection. A new typology of NPS is also proposed here, which 
couples pharmacological effects with chemical classifications, to provide an underlying 
framework for this review.  
Although prevalence of use of NPS remains low by comparison with both established illegal 
drugs such as cannabis and cocaine, and established legal drugs such as alcohol and 
tobacco, this chapter suggests that the significance of the interest generated by NPS relates 
to the rapidity of innovation in manufacturing and retail practices; the speed and scale of 
policy responses; and the relationship between the two, which was initially characterised by 
commentators as ‘cat and mouse’.1 The authors conclude here that the dynamic interaction 
between the NPS market and policy change can be better characterised as ‘hare and 
hounds’ in that legislative control has been a significant driving force in manufacturing and 
retail innovations.  
 
Definitions 
The emergence and evolution of the NPS issue parallels the emergence and evolution of the 
terminology used to describe the appearance of a cluster of psychoactive substances in 
recent years which, unusually for the drugs field, were identified as a potential global threat 
before a significant physical or social problem emerged. The roots of the NPS debate can be 
traced back to the 1970s and the development of the term ‘designer drug’, itself a 
somewhat imprecise term, used to characterise psychoactive substances that were 
                                                          
1 Another metaphor applied to the relationship between pharmacological entrepreneurship and NPS legislative 
control compares this dynamic with ‘cutting off the hydra’s head’ where several more grow back in its place, 
eg. ‘Drugs have been a problem for centuries but legal highs have turned them into a narcotics version of 
Lernaean Hydra’ (http://www.telegraph.co.uk/men/active/mens-health/11310863/Why-the-problem-of-legal-
highs-wont-go-away.html) 
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derivatives of controlled drugs and had been created to circumvent existing legal 
restrictions specifically for recreational purposes. Buchanan and Brown (1988), who ascribe 
the coining of the term to a California pharmacologist called Henderson, identify four main 
categories of ‘designer drugs’: phenylethylamines (eg. MDMA), synthetic opioids, 
methaqualone derivatives and arylhexylamines (eg. phencyclidine or PCP also known as 
‘Angel Dust’, perhaps the most highly publicised of the 1970s designer drugs in the United 
States). However, contrary to the implication that these substances were created by street 
chemists, in fact many of these ‘designer drugs’ were the offshoots or rejects of commercial 
pharmaceutical research and development and hence the details of their synthesis had 
already been published in professional and academic papers (see Brandt et al., 2014 for an 
overview of the development of NPS nomenclature and definitions). Whilst the term 
‘designer drugs’ continued to be used throughout the 1980s and 90s, another term started 
to emerge – ‘legal highs’ – which was an indication of the broadening array of herbal as well 
as synthetic substances available as pills, powders, liquids and vegetable matter that were 
being manufactured and sold to emulate the appearance and effects of existing recreational 
drugs and to evade legislative control. The shift in emphasis here was towards herbal, and 
therefore by implication ‘natural’, products (‘herbal highs’) in contrast to the ‘synthetic’ 
associations of ‘designer drugs’ (also known as ‘research chemicals’). 
In terms of NPS specifically, the watershed moment came in 2008 when the manufacture of 
synthetic cannabinoids and substituted cathinones became an international concern. Such 
were the numbers of new psychoactive substances identified by forensic scientists around 
the world from 2008 onwards that the term Novel Psychoactive Substances (Dargan et al., 
2013) or New Psychoactive Substances was coined (EMCDDA, 2007). For example, the term 
was widely enough accepted in scientific circles that by 2009 the UK Advisory Council on the 
Misuse of Drugs (ACMD) established a “New Psychoactive Substances Working Group” to 
address concerns.2 The definition utilised by the ACMD working group was: “Psychoactive 
drugs which are not prohibited by the United Nations Single Convention on Narcotic Drugs 
or by the Misuse of Drugs Act 1971, and which people in the UK are seeking for intoxicant 
use.” (ACMD, 2011: 10.) 
                                                          
2 8th October 2009, Measham in attendance. 
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Similarly the definition utilised by the UK Association of Chief Police Officers (ACPO) at this 
time also emphasised legal status – specifically the lack of legislative control within the UK – 
as the defining feature in its definition: “New Psychoactive Substances or so called ‘legal 
highs’ are substances which produce the same, or similar effects, to illegal stimulant drugs 
such as cocaine and ecstasy, but are not controlled under legislation [the Misuse of Drugs 
Act 1971 in the UK]. They are however, considered illegal under current medicines 
legislation to sell, supply or advertise for ‘human consumption’” (ACPO, 2011: 19). This 
emphasis on circumventing legislative control led Newcombe to suggest that ‘legal highs’, 
the term still favoured by the media and in everyday conversation, could more accurately be 
considered “legal loophole” drugs (Newcombe, 2012a). Most recently the acronym NPS has 
increasingly emphasised New Psychoactive Substances (eg. NPS Review Expert Panel, 2014) 
rather than Novel Psychoactive Substances (eg. ACMD, 2011; Dargan et al., 2013), in 
recognition that whilst their recreational use might be a relatively recent concern, the drugs 
themselves were not necessarily novel in that at least some of them had an established, if 
not unproblematic, history of pharmaceutical development.  
The United Nations Office on Drugs and Crime (UNODC) has clarified the meaning of ‘new’ 
in their definition of NPS: “substances of abuse, either in a pure form or a preparation, that 
are not controlled by the 1961 Convention on Narcotic Drugs or the 1971 Convention on 
Psychotropic Substances, but which may pose a public health threat. The term ‘new’ does 
not necessarily refer to new inventions – several NPS were first synthesized 40 years ago – 
but to substances that have recently emerged on the market and which have not been 
scheduled under the above Conventions” (UNODC, 2013: 2). Other variations in the NPS 
literature include ‘emerging’ in place of ‘novel’ or ‘new’ and ‘compounds’ or ‘drugs’ instead 
of the more general term ‘substances’.  
The definition and scope of NPS continues to evolve and expand to include both controlled 
and uncontrolled psychoactive drugs, synthetic and natural substances, as well as 
substances that are inadvertently consumed as adulterants or substitutes to the drug of 
choice.3 With so much emphasis placed on defining, identifying and cataloguing new NPS 
                                                          
3 Two examples of these are firstly, BZP which was mis-sold as ecstasy in the UK in 2009/10 and appeared 
widely in forensic analyses of police seizures but had negligible reported use in general population surveys 
(Hoare and Moon, 2010) and self report surveys (Measham et al., 2011a; Measham et al., 2011) at that time. 
PMA/PMMA was banned under UK generic legislation in 1977 and has been mis-sold as ecstasy, particularly 
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through national and international warning systems (EMCDDA 2014a), as well as monitoring 
the websites that sell them (Schifano et al 2010), this has resulted in a somewhat 
‘trainspotter’ approach to charting the field. Indeed the European Monitoring Centre for 
Drugs and Drug Addiction [EMCDDA] annual report graph which charts the new additions to 
the NPS cornocopaeia each year has become an essential element of NPS conference 
presentations in this field. 
Unsurprisingly, given the wide variations in definitions of NPS, the consequent identification 
and publication of NPS-related problems and mortality rates themselves have been 
contentious, highly publicised and highly politicised (King and Nutt, 2014; Goodair et al., 
2014). Whilst Cope from the UK Office for National Statistics argued that “there is no official 
definition of a new psychoactive substance” (2014: 1715), perhaps the closest to a 
consensus is the EMCDDA definition. Article 3 of EMCDDA Council Decision 2005 defines 
New Psychoactive Substances as “A new narcotic or psychotropic drug, in pure form or in 
preparation, that is not controlled by the 1961 United Nations Single Convention on 
Narcotic Drugs or the 1971 United Nations Convention on Psychotropic Substances, but 
which may pose a public health threat comparable to that posed by substances listed in 
these conventions”, a definition which was adapted for use by the UK New Psychoactive 
Substances Ministerial Review Expert Panel (2014:4). However, this definition of NPS is 
weakened by the ambiguity of ‘new’ and the redundancy of ‘may pose a public health 
threat’ given that all drugs carry some degree of risk. 
 
The legal conundrum 
A notable feature in the evolution of the term has been the reduced emphasis on legal 
status which leads to the central unanswered question: exactly what is new or novel about 
New Psychoactive Substances? A definition which focuses on legal status (eg. ACMD, 2011) 
is no longer relevant for many contemporary legislative jurisdictions as we have a situation 
where NPS are rapidly and broadly controlled through ‘blanket bans’, analogue legislation, 
                                                                                                                                                                                    
from 2012 onwards. Four high profile deaths over the Christmas 2014 holiday period were attributed to pink 
‘Superman’ tablets sold as ecstasy but which contained a high dose of PMMA (http://www.bbc.co.uk-england-
suffolk-30709953). Blue ‘Batman’ tablets sold in the UK in 2014 were reported to contain a large amount of 
NBOMe, while other tablets sold as ecstasy were reported to contain methylone or 4-MTA 
(http://www.independent.co.uk/life-style/health-and-families/features/the-evolution-of-ecstasy-from-mandy-
to-superman-the-effects-of-the-drug-mdma-9959732.html) 
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generic legislation, temporary controls and amendments to existing drug controls.4 In the 
UK for example, many NPS are already controlled through generic legislation shortly after or 
even considerably before they make an appearance and without recourse to established risk 
assessment processes for individual substances that were previously central to many policy 
structures but which are now considered too cumbersome in the face of the speed and 
scale of NPS development. This has led to a cycle of rapid and wide ranging legislative 
change which is illustrated in the UK’s use of generic legislation which prohibits the 
possession and supply of whole families of drugs without individual risk assessments. The 
government’s NPS Review Expert Panel reported that “over 550 NPS have been controlled 
since 2009, with 350 controlled since July 2010 … The UK has banned the majority of NPS 
seen in the EU since 2005. Of the 410 NPS identified in Europe up to 2014 … over 85% of the 
main groups are already controlled” (2014: 17).  
Whilst most of the changes to NPS terminology have resulted in a net widening effect, it is 
interesting to note that some definitions have resulted in a reduction in the number or scale 
of drugs covered. As NPS have been controlled, illegal markets have developed and some 
NPS use has bedded in and become established into the repertoires of drug users and 
suppliers. Consequently some NPS, most notably mephedrone, are now documented 
separately to other/all NPS in official reports (eg. Public Health England, 2014).  
A definition which centres on the novel element overlooks the continuities between 
pharmaceutical and recreational drug developments in recent years and also the 
appearance of ‘new’ drugs and their use by recreational users before, as well as after, 2008. 
However, as the NPS definition has evolved to include both legal and illegal drugs, so it has 
come to include “substances that are not necessarily new but which have recently been 
increasingly abused” (International Narcotics Control Board, 2013: 36). This net-widening 
has meant that some of the broadest NPS definitions now include: 
i. not particularly ‘new’ illicit drugs (eg. ketamine, GHB/GBL), and in some cases more 
traditional illicit drugs (eg. psilocybe, khat) whose recreational use has been increasingly 
noted in some dance club scenes from the 1990s onwards (Measham et al 2001), and 
                                                          
4 Space constraints preclude a detailed discussion of NPS policy options and implications, which can be found 
elsewhere (eg. NPS Review Expert Panel, 2014). 
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including psilocybe and khat products that were sold from ‘headshops’ prior to their 
prohibition (2005 and 2014, respectively) in the UK); 
ii. a merging of NPS with ‘club drugs’ or ‘dance drugs’ (notably ecstasy, cocaine and 
amphetamines); 
iii. long standing uncontrolled psychoactive drugs (eg. nitrous oxide, ‘poppers’); 
iv. medicines which are legally manufactured and prescribed, and which again only recently 
were recognised as having any recreational appeal. Although ‘indirectly’ psychoactive 
(intoxication effects are typically described as ‘side effects’), these various medications 
and pharmaceuticals can also be obtained without prescription from online pharmacy 
websites, some of which also sell the more popular NPS. These include psychiatric drugs 
(eg. anti-depressants, anti-psychotics); sleeping pills (eg. chlorals, Z-drugs); analgesics 
with recently recognised abuse potential (eg. tramadol, pregabalin); and wholly or 
predominantly physiological drugs, including sexual potency drugs (eg. sildenafil), 
performance enhancing drugs (notably steroids), cognitive enhancing drugs (eg. 
modafinil) and image enhancing drugs (such as melanotan and botox).  
Significantly, most definitions of NPS exclude the ‘new’ forms and uses of the three main 
legally regulated drugs around the world, namely caffeine (eg. caffeine tablets, powder, and 
even shampoos; high strength ‘energy’ drinks); alcohol (eg. alcohol powder or ‘palcohol’, 
inhalable alcohol vapour); and nicotine (eg. e-cigarettes, shisha, and medicinal nicotine 
products). 
As we can see, the ongoing evolution of terms in the field of NPS studies has blurred what 
were once considered fairly clear distinctions. In particular – and despite ‘legal highs’ still 
being the most commonly used term for NPS in the media and everyday conversation – the 
legal/illegal distinction causes increasing problems given the national and temporal 
differences in drug laws, along with the variations implicit in the term ‘legal’ (notably 
regarding production, supply and use). Consequently, attempts at precise definition often 
lead to semantic dances about what NPS are not, such as: any psychoactive drugs which are 
not legally controlled, more particularly meaning not legally controlled for medical use, not 
legally prohibited, and not licensed for recreational use. Unsurprisingly, a series of 
alternative terms has emerged, with NPS – which potentially sidesteps the legal/illegal 
distinction – coming to dominate. The broadest and most flexible definition of the ‘new’ 
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prefix of NPS would be: legal or illegal drugs which have been recently discovered, 
marketed, and/or notably consumed. An operational definition of ‘new’ could also specify a 
cut-off year relating to the rise of these ‘new drugs’ markets, such as the 2008/09 
mephedrone ‘watershed’ in the UK discussed further below, with NPS relating as much to a 
new cultural phenomenon as to specific psychoactive drugs. In this way NPS could be 
characterised as a flexible collective noun more akin to terms such as ‘dance drugs’ or ‘club 
drugs’ (Coomber et al 2013). 
Some colloquial terms for groups of NPS have also been coined by researchers across the 
globe. The main examples include ‘research chemicals’ for synthetic NPS (notably 
hallucinogens); ‘herbal highs’ for plant-based NPS; ‘spice’, ‘mamba’, or ‘herbal incense’ for 
synthetic cannabinoids; ‘bath salts’ for stimulants (particularly for cathinones in North 
America); and ‘smart drugs’ or ‘nootropics’ for eugeroic stimulants (see Table 1 below). 
To conclude, our assessment of the evolution of the terms and concepts which describe and 
demarcate NPS includes consideration of the role of historical and socio-cultural context to 
this definition. Thus, given the semantic ambiguities and cultural variations of this still 
developing term, this chapter adopts the following operational definition of NPS: those 
drugs emerging or rising significantly in use after the 2008 mephedrone ‘watershed’, 
starting with first generation synthetic cannabinoids and cathinones, followed by a widening 
array of substances which are typically uncontrolled to begin with. Drugs controlled and/or 
whose recreational use was established before 2009 and those in the four categories 
outlined above are largely absent from the later sections of this chapter unless included in 
our summaries of other studies that include them.  
 
Classifications of NPS – towards a new taxonomy 
In order to review the evidence on NPS - and to design research studies - it is necessary to 
go beyond the sculpting of clear and precise definitions such as those discussed above, to a 
principled classification of NPS. Therefore, in this section, we briefly examine the available 
conceptual frameworks for categorising NPS - that is, models developed to organize and 
classify specific NPS into broader categories according to rules of inclusion and exclusion. 
Whilst a variety of classification systems exist in the literature, few are widely accepted 
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across all disciplines and professional groups involved with NPS, and the constantly evolving 
nature of NPS means that they can rapidly become outdated. The most common four 
dimensions of extant classifications are: by source, by legal/medical status, by psychoactive 
effect (on the brain and mind), and by chemical group. We discuss these four dimensions 
below before presenting a new multi-level classification of NPS based on two of the most 
important dimensions. 
Source classification 
The source classification is relatively straightforward: NPS can be broadly divided into 
natural and synthetic drugs. Natural NPS can be sub-divided into plant-based drugs (eg. 
salvia, peyote, amanita muscaria) and animal-derived drugs (eg. cane-toad skin excretions). 
Plant-based drugs (or plant extracts) are an NPS category frequently used by researchers. 
Synthetic NPS can be sub-divided into semi-synthetic drugs (production of which starts with 
a natural drug) and fully synthetic drugs (made without recourse to natural drugs). A third 
classification by source is ‘electronic highs’, though these are outside the scope of this 
chapter (Newcombe, 2012b). Also, as noted above, some NPS products contain a mixture of 
natural and synthetic drugs: notably ‘synthetic cannabis’ products, which may contain minor 
plant-based drugs mixed with synthetic cannabinoids (Uchiyama et al, 2010). 
Legal classification 
Another common way of classifying NPS is by their legal status, which derives from national 
legislation assigning controlled drugs to classes/schedules, with criminal penalties for 
possession and trafficking offences reflecting the level of legal categorisation. This system is 
not fixed but constantly evolves as new legislation to control emerging NPS is introduced, 
and as laws in different countries are amended to allow new or revised categorisations. 
National legislation on drugs, typically enacted in Medicine Acts, also covers medical and 
non-medical aspects of NPS use and supply (notably regulations on prescribing and 
dispensing). International legislation derives from the United Nations (notably the three 
drugs conventions) and in Europe from the European Union (EU) Parliament. 
Focusing on the UK, NPS are categorised by the Misuse of Drugs Act 1971 (MoDA) in two 
ways: by three classes (A to C) which determine the penalties for possession and trafficking 
offences (up to life imprisonment for trafficking class A drugs); and by five schedules (1 to 5) 
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which regulate prescribing and dispensing (the strictest being schedule 1, which means the 
drug has no recognised medical use). Over the 21st century, a growing number of NPS and 
new/problematic medical drugs have been legally controlled in the UK by successive 
amendments to the MoDA (see Table 1). 5 
  
                                                          
5 In 2011, the UK MoDA was amended to allow for the passing of a ‘temporary class drug order’ (TCDO) which 
bans the sale (but not possession) of a potentially harmful new drug for a period of approximately 12 months 
to allow an assessment to be made of the need for permanent restrictions on sale and possession. In the first 
two years, three drugs were placed under a TCDO - methoxetamine, 5/6-APB and NBOMe compounds – all of 
which were subsequently banned (see Table 1). 
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Table 1: Drugs controlled in the UK in the 21st century, by amendments to 1971 Misuse of 
Drugs Act 
YEAR DRUGS CLASS & 
SCHEDULE 
2001  35 phenethylamines A1 
2003  GHB (gammahydroxybutyrate) C4i (C2 from 
1/15) 
2005  psilocin-based mushrooms (live/fresh) 
 ketamine 
A1 
C4i (B3 from  
6/14) 
2009  1ST generation synthetic cannabinoids 
 GBL (gammabutyrolactone), 14BD (butanediol) 
 BZP (benzylpiperazine) & other piperazines 
B1 
C 
C1 
2010  mephedrone & substituted cathinones B1 
2012  2DPMP (desoxypipradol/Ivory Wave) 
 phenazepam 
 pipradol esters & ethers (piperidines) 
B1 
C2 
C3 
2013  2nd generation synthetic cannabinoids 
 methoxetamine 
 desmethyltramadol 
 lisdexamphetamine 
 zopiclone & zaleplon 
B1 
B1 
B1  
B2 
C4i 
2014  NBOMe compounds 
 benzofuran compounds (5-APB, 6-APB) 
 khat 
 tramadol 
A1 
B1 
C1 
C3 
2015 
 
 dimethylaminorex (4,4’-DMAR) 
 cyclohexyldiphenylethylpiperazine (MT-45) 
 tryptamine compounds (AMT, 5-MeO-DALT) 
 lysergamides: ALD-52, ETH-LAD, PRO-LAD, AL-LAD, LSZ 
 AH-7921 (opioid) 
Planned 
 3rd generation synthetic cannabinoids  
 psychoactive Substances Bill proposing ‘blanket ban’ on sale 
of all psychoactive substances with some exemptions 
 possible ban on all drugs affecting CB1 brain receptor 
 
Reclassification and rescheduling 
2004 cannabis  C1 (from B1) 
2007 methamphetamine A2 (from B2) 
2009 cannabis  B1 (from C1) - except Sativex (B4i)  
2014 ketamine  B2 (from C4i) 
2015 GHB   C2 (from C4i) 
 
A1 
A1 
A1 
A1 
A1 
 
A1 
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Psychopharmacological classification 
Perhaps the most common ways of classifying NPS are by their psychoactive effects and 
chemical groups, including their impact on neurotransmission. The taxonomy of NPS 
presented here was influenced by several sources including drug definition and classification 
schemes used on such websites as Wikipedia and Erowid, along with models implicitly or 
explicitly identified by researchers, trainers and organizations (EMCDDA, 2014a; Dargan & 
Wood, 2013; Mentor-Adepis, 2014; Zohara et al., 2014).6 Adley’s Drug Wheel is particularly 
useful, combining seven categories of broad psychoactive effect - depressants, opioids, 
stimulants, cannabinoids, empathogens, psychedelics and dissociatives – with a two-way 
classification by legal status in the UK (http://thedrugswheel.com/). By April 2015 it covered 
100 drugs/drug groups, including 69 controlled substances and 31 non controlled 
substances. Its main limitations are the relevance of its legal classification to the UK only 
and its basis in just one psycho-chemical classification level. 
In our proposed classification of NPS, psychoactive drugs can be organised according to a 
conceptual framework founded on two primary orthogonal dimensions of altered brain 
activity: stimulant-depressant and hallucinogenic-antipsychotic. However, with the notable 
exception of cannabidiol, there are very few psychoactive substances with predominantly 
anti-psychotic effects in common use. Accordingly, our scheme bases the first categorisation 
level (general effect on the CNS) on the tripartite distinction between depressants, 
stimulants and hallucinogens. The second level categorises NPS into nine families of 
psychoactive effect, namely: inebriant, sedative and analgesic families of depressants; 
euphoriant, eugeroic and entactogen families of stimulants; and psychedelic, dissociative 
and deliriant families of hallucinogens. The third level categorises NPS into 37 chemical 
groups, and the fourth category itemises the hundreds of drugs which come under these 
                                                          
6 Recent reviews of the evidence about particular categories of NPS include: amphetamines (Lapoint et al. 
2013); cannabinoids (ACMD 2014, Auwarter et al. 2013, Kickman & King 2014, Linnell 2014); piperazines (Gee 
& Schep 2013); cathinones (ACMD 2010, Wood & Dargan 2013); pipradols (White & Archer 2013); 
aminoindanes (Brandt et al, 2013); arylcyclohexylamines (Chan et al, 2013, Greene 2013); phenethlyamines 
(King 2013); benzofurans (Greene 2013); dimethoxyphenethylamines/NBOMe (ACMD 2013); and tryptamines 
(ACMD 2014, Greene 2013). 
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headings7 - these can be further divided into legal and illegal drugs according to national 
laws. It should be noted that there are many types and levels of chemical classification and 
the categories used in Table 2 are open to further refinement.8  
Table 2 presents the taxonomy of drugs considered to be NPS according to at least some of 
the many definitions discussed above, which cover both ‘new’ drugs and ‘legal’ drugs, as 
well as drugs available from High Street ‘headshops’, online websites and other sources in 
the case of drugs such as laughing gas, poppers, khat and magic mushrooms. The scheme 
can also be modified and tightened to focus on NPS by our earlier operational definition (at 
the levels of chemical group and specific drugs). Clearly, given that the effects of drugs vary 
widely by sub-types and consumption patterns (eg. route of use, dose, setting), some drugs 
or drug categories could arguably be classified under alternative headings. For instance, the 
entactogen family could be included under the class of hallucinogens or stimulants, because 
entactogens vary widely in their effects and when consumed in different ways. Similar 
considerations apply to cannabinoids Even so, our taxonomy provides a useful framework 
for understanding and discussing NPS and will be used to organise the evidence which 
follows. 
 
  
                                                          
7 Specific chemicals sold as NPS branded products are also given trade names by manufacturers and retailers 
but these are not used here. 
8 Space constraints preclude a more detailed discussion here. More detailed definitions of these classes of 
drugs, covering their chemistry and psychopharmacology, can be found on such websites as Erowid and 
Wikipedia. 
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Table 2: A new taxonomy of New Psychoactive Substances  
Psychoactive Effect Chemical Classification 
Class Family Group Specific NPS 
Depressant Sedative  Benzodiazepine 
 Anti-histamine 
 
 GHB-type 
 Kavalactones 
 Z-drugs 
phenazepam, etizolam, brotizolam 
diphenhydramine, promethazine, 
cyclizine 
GHB, GBL, GBK, 14BD 
methysticin, yangonin, kavain [kava: 
15] 
zopiclone, zaleplon 
Analgesic  Opioid 
 
 Kratom compound 
MT-45, AH-7921, doxylam, carfentanil, 
ocfentanil 
mitragynine, hydroxymitragynine 
Stimulant Euphoriant  Amphetamine 
 
 Cocaine analogue 
 Cathinone - natural 
 Pyrrolidine 
 Piperazine 
 Piperidine 
 Oxazoline 
 
 Aliphatic amine 
fluoroamphetamine, 4-
methylamphetamine 
dimethocaine, fluorotropacocaine 
cathinone, cathine [khat] 
naphyrone, pyrovalerone, MDPV 
BZP, TFMPP, mCPP, MeOPP 
pipradol, 2DPMP, DPMP, 
ethylphenidate 
methylaminorex, dimethylaminorex 
(DMAR) 
dimethylamylamine (geranamine) 
Eugeroic  Pyridine 
 Xanthine 
 Benzhydril-sulfinyl 
 Ephedrine 
nicotine, arecoline, cotinine, cytisine 
caffeine, theobromine/theophylline 
modafinil, armodafinil, adrafinil 
ephedrine, pseudo-ephedrine, cathine 
Entactogen  Phenethylamine 
 
 Cathinone - 
synthetic 
 Aminoindane 
 Benzofuran 
25B-NBOMe, 25I-NBOMe, bk-2CB, 
mescaline 
mephedrone (m-cat), methylone, 
methedrone 
MDAI, MMAI, 5-IAI, 2-AI, TAI, ETAI 
5/6-APB, bromo-dragon FLY, 2C-B-FLY 
Hallucinogen Psychedelic  Lysergamide 
 Tryptamine 
 Cannabinoid (SCRA) 
 Harmala alkaloid 
LSA, LSH [ipomea] 
AMT, AET, 5-MeO-DALT, 4-HO-MET 
JWH-018, AM-2201, CP-47, 5F-AKB-48, 
XLR-11 
harmaline, harmine (beta-carbolines) 
Dissociative  
Arylcyclohexylamine 
 Other NMDA-RA 
 Diterpenoid 
 Isoxazole 
methoxetamine, dephenidine, 
tiletamine 
nitrous oxide, dextromethorphan 
salvinorin-A [salvia] 
muscimol, ibotenic acid [amanita] 
Deliriant  Alkyl nitrite 
 Anti-cholinergic 
amyl nitrite, butyl nitrite, isopropyl 
nitrite 
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 Hydrocarbon 
 Haloalkane 
atropine, scopolamine, hyoscyamine 
toluene, butane, petroleum 
chloroform, chlorofluorocarbons 
(CFCs) 
 
KEY 
NMDARA: N-methyl-D-aspartic acid receptor antagonist 
SCRA: synthetic cannabinoid receptor agonist 
[ ] = plant source 
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Trends in NPS production, supply and use 
This section provides a brief overview of the main evidence concerning the development of 
NPS markets, including trends in production, distribution, availability, prevalence of use and 
consumption. 
The challenges of defining and measuring drug use in general have been widely discussed 
elsewhere in this collection, and in relation specifically to NPS here. These ongoing 
challenges make estimating the prevalence of use – across drugs and population groups – 
even more complex. Moreover, allowing for the usual caveats for drug prevalence research 
(Newcombe, 2007), NPS research is even more challenging because of the large numbers of 
substances, their rapid development and changing legal status, and the complexities of 
identifying and matching chemical compounds with branded retail products and the street 
or slang names adopted by different user groups. The lists of actual and potential drugs cast 
an increasingly gloomy shadow across research on patterns and prevalence of NPS use. This 
has led some researchers (including one of the authors) to embrace greater cross 
disciplinary collaboration and triangulation in order to explore what users have bought and 
believe they are consuming by comparison with what retailers have bought from 
manufacturers and believe they are selling - resulting in fertile collaborations between 
criminologists, chemists and toxicologists (eg. Archer et al., 2014a, b). Whilst urine testing as 
a validation tool for self reported drug use is nothing new (eg. Measham et al., 2001), the 
scale of mass pooled urine analysis in recent years across Europe (EMCDDA ,2014b) in large 
part has been fuelled by the rapid expansion in the number of NPS and the need to 
ascertain their prevalence of use whilst challenging the constraints of traditional self report 
data collection. 
Global NPS use 
The World Drug Report (UNODC 2014: 51) has reported that NPS use is now “a truly global 
phenomenon”. Of 103 countries on which relevant information was available in December 
2013, 94 reported the emergence of NPS markets, up from 70 out of 80 at mid-2012. The 
total global number of NPS has more than doubled from 166 in 2009 to 348 at the end of 
2013 (including 97 NPS identified for the first time in 2013). This has led to the 
unprecedented situation of “the number of NPS clearly exceed[ing] the number of 
psychoactive substances controlled at the international level” (UNODC 2014: 52): that is, 
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348 NPS compared with 234 controlled drugs. The main drug groups comprising the 348 
NPS included cannabinoids (29%), phenethlyamines (21%), cathinones (15%), tryptamines 
(8%), plant-based drugs (6%), piperazines (4%), arylcyclohexylamines (3%), aminoindanes 
(1%), and other NPS groups (11%). 
The Global Drug Survey (GDS) accesses predominantly young adults through a range of 
general and specialist media websites such as The Guardian, Fox News and Mixmag. The 
2013 GDS was based on a self selecting convenience sample of 78,800 people (Winstock, 
2014). Across the 18 countries with sample sizes of over 600 (average sample size: 4,000), 
12% reported having used NPS/‘legal highs’ in the last year (using a broad definition of NPS 
which includes longstanding and non synthetic psychoactive substances including nitrous 
oxide and salvia) and 22% reported having bought drugs online. Of the ten types of NPS use 
reported, last year use of nitrous oxide was the most common (6%), reported by 14 
countries and ranging from 1% in Portugal to 27% in the Netherlands. The other two most 
popular NPS were salvia and synthetic cannabinoids, with national rates of use ranging from 
1% to 10%. The report on the December 2014 GDS noted that there was a substantial drop 
in last year NPS use to 7% (Winstock, 2014). Among the 11 countries with over 1,500 
respondents, last year use of NPS varied from below 10% in nine countries to 12% in the UK. 
Overall, the most commonly reported ‘research chemicals and legal highs’ were synthetic 
cannabinoids: 2% reporting having used them in the last year.  
A review of the literature on the epidemiology of NPS use by Sumnall and colleagues 
concluded that aside from mephedrone, salvia divinorum and SCRAs “most other NPS 
appear not to have made a significant impact on the drug market with respect to use 
preference … [and] remain infrequent choices” (2013: 99). They note that “most data on 
NPS epidemiology comes from (small) convenience samples”, which produce findings with 
limitations given that “such data can only reveal drug use behaviours in the respondents 
surveyed, and cannot easily be generalized beyond the study” (2013: 99). Although the 
authors did not mention that nitrous oxide use is second only to cannabis in the UK and is 
the most popular NPS in the UK general population survey (Home Office, 2014), this may be 
because nitrous oxide only recently was included in (some) definitions of NPS. 
 
USA 
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The US office of National Drug Control Policy (2014) reported that the number of new 
synthetic drugs identified in 2012 reached a record 158, including 51 cannabinoids 
(compared with two in 2009), 31 cathinones (compared with four in 2009), and 76 other 
new drugs. The number of hospital emergency department visits involving synthetic 
cannabinoids more than doubled from 11,406 in 2010 to 28,531 in 2011 (Substance Abuse 
and Mental Health Services Administration, 2013). 
Indeed, research consistently indicates that synthetic cannabinoids are the most popular 
type of NPS in the USA, although it should be noted that this depends on how NPS are (or 
are not) defined and classified, including which NPS are itemized in survey questionnaires 
and which NPS are included under standard drug group headings in surveys. For instance, 
the Monitoring the Future (MtF) self report annual surveys of US college students and young 
adults, based on repeated cross sectional surveys of high school graduates, have been 
reported from 1976 to 2013 (Johnston et al., 2014b). The MtF surveys of over 40,000 
secondary school students and several thousand college students and young adults aged 19 
to 28 years has reported the prevalence of last year use of three itemized NPS in recent 
years (see Table 3) (Johnston et al., 2014a,b). However, it is likely that drugs classified as 
NPS in some other studies or reporting systems are incorporated under general drug group 
headings in the MtF study – including hallucinogens (eg. NBOMe), inhalants (eg. nitrous 
oxide), tranquillizers (eg. phenazepam) and opioids (eg. MT-45).  
 
Table 3: NPS use among 8th to 10th graders in US secondary schools, and college students 
and young adults, 2009 to 2014 
 Synthetic cannabis Synthetic stimulants Salvia divinorum 
 8th  10th  12th  CS YA 8th  10th  12th  CS YA 8th  10th  12th  CS YA 
2009             5.7 5.8 3.5 
2010           1.7 3.7 5.5 3.5 3.6 
2011   11.4 8.5 7.4      1.6 3.9 5.9 3.1 2.2 
2012 4.4 8.8 11.3 5.3 5.3 0.8 0.6 1.3 0.3 0.5 1.4 2.5 4.4 1.5 1.5 
2013 4.0 7.4 7.9 2.3 3.2 1.0 0.9 0.9 0.1 0.4 1.2 2.3 3.4 1.0 0.9 
2014 3.3 5.4 5.8   0.5 0.9 0.9   0.6 1.8 1.8   
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CS: college students 
YA: young adults (19-28 years) 
 
In 2014, levels of last year use of synthetic cannabinoids (also referred to as ‘K2/Spice’) 
ranged from over 3% among 8th graders to almost 6% among 12th graders. These represent 
significant drops from the previous year, and levels for all three grades have dropped 
steadily since 2012. Levels of last year use of salvia also dropped two to three-fold from 
2010 to 2014 to below 2%, and last year use of synthetic stimulants (‘bath salts’) was 
reported by fewer than 1% of students in all grades in 2014. Levels of last year use of all 
three NPS have fallen fairly steadily across recent years for both groups, and to lower levels 
than those for school students by 2013 – 3% or lower for cannabinoid use, and 1% or lower 
for use of salvia and stimulants.  
 
Prevalence of NPS use across Europe 
The Early Warning System run by EMCDDA (2015) reported that more than 450 NPS were 
currently being monitored across the EU. Overall 299 different NPS were detected in 2013: 
101 newly identified and 198 previously identified NPS. The most commonly identified types 
since 2008 were synthetic cannabinoids (134) and cathinones (77). NPS identified for the 
first time reached a record 101 in 2014, compared with 81 in 2013, 74 in 2012, 49 in 2011, 
41 in 2010, 24 in 2009, and 13 in 2008. The most common new types identified over the last 
two years were: cathinones (from 7 in 2013 to 31 in 2014), cannabinoids (from 29 to 30), 
phenethlyamines (from 14 to 9), arylalkylamines (from 7 to 4), opioids (from 5 to 5), 
tryptamines (from 1 to 5), benzodiazepines (from 2 to 4), and other synthetic substances 
(from 16 to 13). 
 
Seizure figures for 2013 show that there were a record 46,370 seizures of over 3.1 tonnes of 
NPS, with the two main types including 21,495 seizures of almost 1.6 tonnes of synthetic 
cannabinoids, and 10,657 seizures of more than 1.1 tonnes of synthetic cathinones. There 
was a seven-fold increase in reported NPS seizures between 2008 and 2013. 
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The EMCDDA (2013) identified 651 shops that sold NPS as ‘legal high’ products or ‘research 
chemicals’, a slight decrease on 693 in January 2012, but higher than the 631 in July 2011, 
314 in January 2011, and 170 in 2010. The July 2011 snapshot exercise found that the three 
NPS most commonly sold by the online shops at that time were all plant products: kratom 
(128), salvia (110), and hallucinogenic mushrooms (72). The next three most commonly sold 
NPS were synthetic drugs: MDAI (61), methoxetamine (58) and 6-APB (49) (EMCDDA 2011a, 
b). The UK was home to 121 of the shops. 
The European Commission ‘Flash Eurobarometer’ survey of ‘young people and drugs’ was 
based on telephone interviews with over 13,000 15 to 24 year olds in all 28 EU Member 
States in June 2013. The average EU figure for reported lifetime use of NPS increased from 
5% in the 2011 survey to 8% in the 2014 survey (EC 2014). The top six countries for NPS use 
all exhibited increases in lifetime use of NPS from 2011 to 2014: Ireland (from 16% to 22%), 
Slovenia (from 7% to 13 %), Slovakia (from 7% to 13%), Spain (from 5% to 13%), France 
(from 5% to 12%), and UK (from 2% to 10%). The biggest increase was in the UK, where the 
proportion of NPS users increased fivefold between the two surveys. 
 
NPS availability and use in the UK 
 
Official statistics 
Though national NPS seizure figures are not available, the number of seizures of NPS in 
prisons in England and Wales has been reported to have increased significantly, from 16 in 
2010, 90 in 2011, 138 in 2012, 267 in 2013, and 436 in the first 7 months of 2014 
(Parliamentary Question, September 2014). Each year, the vast majority of these seizures 
involved synthetic cannabinoids (from 15 in 2010 to 430 in the first half of 2014), and the 
prison authorities have reported that use of these NPS leads to increased violence and 
disorder among inmates. A qualitative study of NPS that included interviews with prisoners 
and ex-prisoners also reported that synthetic cannabinoids are the most popular drug in UK 
prisons (Linnell et al, 2015).  
The 2013/14 annual report of the UK Forensic Early Warning System (FEWS) noted that “so 
far the Coalition Government has controlled over 350 NPS, by group or generic definitions, 
 21 
including some not seen in the UK, under the 1971 Act” (FEWS, 2014: 4).9 The total number 
identified since 2011 was 31, including 10 cannabinoids, four tryptamines, three 
phenethlyamines, and three cathinones. Analysis of NPS samples collected by FEWS found 
that around nine out of ten were mixtures of either two (61%) or three (30%) active drug 
ingredients. In 2013/14, 3% of internet and 4% of headshop samples contained controlled 
NPS, compared to 16% and 64% in 2012/13. However, 88% of festival samples contained 
controlled drugs in 2013/14, a similar amount to 2012/13 (84%) (FEWS, 2014). 
An NPS was the primary drug10 of concern for 144 people in drug treatment in England in 
2013/14 – just under 0.1% of all drug treatment clients (Public Health England, 2014). 
However, separate statistics for mephedrone and GHB/GBL indicated that the number of 
NPS users in treatment had almost tripled over the last three years. 
 
General household surveys 
Annual general household surveys of drug use are conducted in all countries of the UK but 
due to space constraints, we focus here on prevalence surveys in England and Wales only 
(see UK Drug Focal Point, 2014, for a summary of NPS use across the UK). The annual Crime 
Survey for England and Wales (CSEW) includes a general household survey of drug use 
among over 20,000 adults (Home Office, 2014) and is the most robust national data set on 
drug prevalence in the UK. Over the six years ending 2014/15, the CSEW has reported on 
the prevalence of use of seven types of NPS: mephedrone, spice, khat, BZP, GHB/GBL, 
nitrous oxide and salvia. Overall lifetime and last year use of mephedrone has declined 
steadily for both adults and young adults since it was controlled and national data was first 
collected in 2010, although it rose slightly in 2013/14 (see Table 4).11  
                                                          
9 Examples of NPS seen in the UK market in the past year are: AKB-48 (a synthetic cannabinoid), 25-B-NBOMe 
(a phenethylamine) and 4-MeO-PCP (a dissociative anaesthetic) as well as substances sold under branded 
names such as CRITICAL HAZE (containing 5F-AKB-48), SPARKLEE (containing MPA, 5-MeO-DALT, and 2-
aminoindane) and Black Mamba (containing AM-2201, 5-MeO-DALT and JWH-081)” (FEWS 2014: 4). 
10 Primary use of NPS is defined by the National Drug Treatment Monitoring System (NDTMS) for England as 
drug use which meets these two conditions: (i) no use of opiates or crack in the treatment journey; and (ii) 
report of primary drug in the earliest episode of the latest treatment journey to cross the reporting year, in 
any of the following NPS categories: predominantly stimulant, hallucinogenic, dissociative, sedative/opioid or 
cannabis; or not otherwise specified (Public Health England 2014). 
11 Based on these figures, the total number of lifetime users of mephedrone was estimated to have climbed 
from 584,000 in 2012/13 to 764,000 in 2013/14; while the total number of last year users climbed from 
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Table 4: Prevalence of use of mephedrone in England & Wales, 2010/11 to 2014/15 (CSEW) 
 
 ADULTS 16-59 YOUNG ADULTS 16-24 
 Lifetime Last Year Lifetime Last Year 
2010/11 - 1.3 - 4.4 
2011/12 - 1.0 - 3.3 
2012/13 1.9 0.5 4.5 1.6 
2013/14 2.3 0.6 6.3 1.9 
2014/15 2.2 0.5 5.3 1.9 
 
Nitrous oxide and salvia divinorum  
Both nitrous oxide and salvia remained uncontrolled drugs in the UK at the end of 2014 and 
therefore although not included in many post-2008 definitions of NPS given their 
longstanding if low level recreational usage, they are considered to be ‘legal highs’ by some 
commentators based on their legal status, effects and availability (to date) from online 
retailers and headshops. Between 2012/13 and 2013/14, there were increases in the last 
year use of both of these drugs, for both adults and young adults, with the change in last 
year use of salvia among all adults being statistically significant (Table 5). Nitrous oxide was 
the second most commonly used drug by young adults in the UK after cannabis, and the 
third most commonly used drug by all adults after cannabis and cocaine.12 The figures on 
last year use also show that mephedrone and salvia are the fifth and sixth most popular 
drugs among young adults (ecstasy is fourth).  
 
Table 5: Prevalence of last year use of salvia and nitrous oxide in England & Wales, 2012/13 
to 2013/14 (CSEW, Home Office 2014) 
 
 ADULTS 16-59 YOUNG ADULTS 16-24 
                                                                                                                                                                                    
161,000 to 205,000. By 2013/14, these numbers included 394,000 young adults who had ever used 
mephedrone and 117,000 young adults who had used mephedrone in the last year (Lader 2015). 
12 It can be extrapolated from these figures that the number of last year users of nitrous oxide in the UK 
climbed from over half a million in 2012/13 to nearly three quarters of a million in 2013/14. 
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 Salvia Nitrous Oxide Salvia Nitrous Oxide 
2012/13 0.3 2.0 1.1 6.1 
2013/14 0.5 2.3 1.8 7.6 
 
The CSEW also reported on last year use of four other drugs between 2009/10 and 2011/12 
which are included in some definitions of NPS. Last year use of ‘spice’ and BZP both fell from 
around half a per cent to 0.1%, while last year use of khat and GHB/GBL remained level at 
about 0.2% and 0.1% respectively. Between 2009/10 and 2010/11, notable drops in last year 
use of all four of these NPS were evident among 16-24 year olds, with 25-59 year olds 
exhibiting stable and lower levels of use. In short, of seven types of NPS assessed by the 
CSEW, three were fairly popular compared with controlled drugs, while four were used by 
fewer than 0.2% according to the latest figures available.  
 
Motivations and user groups 
In this final section we draw together some of the evidence discussed above to piece 
together why the NPS phenomenon shot into the spotlight from 2008 onwards and what 
might be the motivations of users, which then sheds light on who are the key user groups. 
Whilst many of the reasons for taking NPS are similar to the motivations for consuming a 
whole host of other psychoactive substances – legal, illegal or prescription; prohibited, 
controlled or licensed – it is only through an understanding of the inter relationship 
between established and ‘new’ psychoactive substances that we can more fully understand 
their appearance and appeal.  
(1) Purity 
A key reason for the emergence of NPS relates to their relative purity, by comparison with 
established drugs across Europe in that particular historical period (Measham, 2013). 
Forensic analyses of ecstasy and cocaine seizures and submissions to drug checking 
organisations (such as the Dutch Drug Information and Monitoring System or DIMS) in 
2008/10 concur that purity was at its lowest level across Europe just before mephedrone 
became a concern. In the UK for example, purity levels fell to an all-time low for most 
established controlled drugs in around 2009. Cocaine purity reached a low point of 20% in 
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2008 (Table 6) and the MDMA content of ecstasy pills fell to a low point of 20mg in 2009 (UK 
Focal Point 2014), after the emergence of MDMA crystal (MD, Molly) as a higher priced, 
higher purity ‘premium’ product in the mid 2000s in the UK (Smith et al., 2009). Conversely, 
forensic analyses of mephedrone showed that it was being sold at approximately 95% purity 
before legislative control in 2008-10 (Miserez et al., 2014). Whilst it could be argued that it 
was merely coincidence that the purity levels of the most popular established illegal 
stimulants were at their lowest point in decades at the very same time that mephedrone (a 
legal stimulant with not dissimilar effects to cocaine and ecstasy) first became a concern, 
studies with users endorse this connection. Interviews with mephedrone users before 
legislative control in the UK (Measham et al., 2010) articulate a clear narrative of 
disillusionment with Class A drugs by both recreational drug users and Problem Drug Users:  
“I guess it has kind of replaced my desire for ecstasy… because I don’t really feel like I 
can get hold of proper ecstasy. Whereas mephedrone I feel much more comfortable 
taking because I kind of know what I am getting. So in that way it has probably 
replaced my, yes I would say it probably has – until I can find, if I find a good source 
of MDMA – it has replaced my use of that drug.” (Professional male, 34, 2009, in 
Measham et al., 2010) 
From 2011 onwards both DIMS and UK forensic analyses suggest that the purity of cocaine 
and ecstasy increased again across Europe, with the MDMA content of seized ecstasy pills 
increasing five fold from 20mg to 100mg in the six year period 2008-2014 (ACMD 2015). 
Conversely, after legislative control of substituted cathinones in 2010, forensic analyses of 
second generation NPS show that unlike the first generation NPS of high purity, these 
second generation NPS were of variable content and sometimes even illegal (Brandt et al., 
2010). The variable content, effects and legal status of these NPS were widely publicised, 
capitalised on by politicians and drugs prevention campaigns. This may have dampened 
some of the initial demand for NPS and resulted in a fall in NPS prevalence rates in annual 
surveys, including both the general household survey and convenience sample surveys of 
festival-goers (Measham, 2013) and club-goers (Wood et al., 2012a). The rise and fall in self 
reported mephedrone use contrasts with the disillusionment and then reinforcement of 
ecstasy’s appeal as the MDMA content of tablets rose to and surpassed their previous levels 
(Pidd, 2014). So a key point here is that the appeal of NPS products when they first 
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appeared related to the purity and reliability of their contents relative to the purity and 
reliability of established illegal drugs, and the relationship between the two.13  
 
Table 6: Domestic resale mean percentage purity of certain drugs seized by police in 
England and Wales, 2003 to 2013 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Amphetamines 11 9 10 11 11 8 8 8 10 5 7 
Cocaine powder 51 42 43 35 33 29 20 24 26 37 38 
Crack cocaine 70 64 65 50 52 43 27 31 26 30 36 
Heroin (brown) 33 40 47 44 50 43 44 35 18 20 33 
Ecstasy * 65 67 66 48 52 33 44 49 71 102 n/a 
 * mg of MDMA base per tablet 
 Source: UK Focal Point (2014) 
It should not be assumed that there was simple displacement from low purity Class A drugs 
to high purity legal NPS in 2008/9, however. Annual surveys conducted with club-goers at 
South London gay-friendly dance clubs from 2010 onwards have shown consistently high 
levels of self reported mephedrone use each year, with mephedrone becoming the drug 
most likely to be consumed on a night out and also these club-goers’ favourite drug 
(Measham et al 2011a; Wood et al 2012b). However, these surveys found no evidence of 
wholesale displacement from Class A drugs such as cocaine and ecstasy to NPS, but rather 
mephedrone appeared to have been added to existing drug-using repertoires and was being 
used as a supplement, a secondary drug, to ‘top up’ low purity Class As (Moore et al., 2013). 
This is supported by the general population survey (Smith and Flatley, 2011) which reports 
that nine in ten mephedrone users reported having used other illegal drugs in the last year. 
These various studies suggest, therefore, that purity was a particular appeal for users who 
were already experienced Class A drug users, such as club-goers. A further indicator of the 
elasticity of demand for mephedrone and its possible status as a ‘topping up’ drug relates to 
                                                          
13 There is some evidence that purity levels and accurate labelling is increasing again amongst third generation 
NPS products (FEWS 2014; ACMD 2015). 
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the fact that the price only rose to £20/25/gram after legislative control in 2010 and has 
stayed at that price since then.14  
(2) Availability 
This has been a significant driver to NPS use: for the first time psychoactive drugs were 
widely, cheaply and legally available online, in specialist headshops, market stalls, festivals 
and (of increasing concern) at small independent convenience stores and petrol garages 
with variable retail practices (NPS Review Expert Panel, 2014). However, as with purity, 
availability of NPS is also relative and usually gauged in comparison with the access and 
availability of illegal drugs. So for users who either could not access or did not want access 
to established drugs through street ‘dealers’, legal NPS hold an obvious appeal.  
The DrugScope 2013 street drug trends survey, based on information from drugs workers at 
25 agencies in mainland Britain, revealed that the main source of NPS was not internet 
websites but specialist ‘headshops’ and also non-specialist shops such as petrol stations, pet 
shops, takeaway food shops, newsagents, tobacconists, sex shops and market stalls. While 
few young people were coming forward to treatment services, outreach workers reported 
that some young people were at risk of serious health consequences, a finding confirmed in 
the qualitative study by Linnell and colleagues (2015). Daly (2013) also reported that a 
snapshot survey carried out in Newcastle of 116 people (mainly teenagers aged 16–17) 
found that, of those who had recently bought ‘legal highs’, 45 had purchased them from 
headshops, while 20 had bought them from a petrol station or takeaway food shop. 
Availability of NPS appeals particularly to teenagers and novice users without established 
contact with illicit subcultures and illegal economies (evidenced in the disproportionate 
numbers of patients in their mid teens hospitalised for SC-related problems in the UK). 
Others who may not be able to access illegal drugs through street dealers may be residents 
in rural areas without easy access to urban street markets and middle class professionals 
who were suddenly able to order NPS products online with a credit card and without the 
risks associated with purchasing illegal drugs such as being exploited by street dealers or 
caught by the police. The converse of this is that once mephedrone was banned self 
reported use fell (eg. Lader, 2015; Measham, 2013, Winstock, 2014) suggesting that at least 
                                                          
14 Whilst it doubled in price compared with its legal price of £10/gram, it remains at about half the price per 
gram of MDMA and cocaine in the UK. 
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in part, once availability plummeted, so did use. Furthermore, for those who continued to 
use controlled NPS, their use was likely to be more risky in terms of both physical and social 
harms due to greater variations in content and purity in unregulated markets combined 
with accessing criminal supply networks.  
(3) Legality 
If prevalence of NPS use falls in the years after legislative control, as indicated with falling 
mephedrone use in the UK general household survey discussed above (Lader 2015), then 
perhaps this can be seen as evidence of a deterrent effect of banning drugs, as distinct from 
the impact of reduced availability resulting from the ban on legal sales? In general there is a 
weak evidence base on the deterrent value of criminal law. What we know from 
international comparative drug policy analyses (eg. EMCDDA, 2011c; Stevens, 2011) and 
regional times-series data (eg. Wood et al., 2012b) is that there appears to be little impact 
of drug policy change on drug use in a range of different jurisdictions.  
Furthermore, in surveys and interviews, users themselves rarely prioritise legal status when 
discussing why, or indeed why not, to take illegal drugs (eg. Parker et al., 1998). Research 
with users has found that more important reasons for taking or avoiding drugs include price, 
purity, availability, perceived pleasurable/unpleasant effects, curiosity and the wider social 
context to use (Norman et al., 2014; O’Brien et al., 2015). Moreover, if, as discussed above, 
NPS users are more likely to be experienced drug users and take NPS along with illegal drugs 
in weekend polydrug repertoires, then the legal status of NPS in particular is of little 
relevance. 
Where legal status has been found to result in a significant appeal for uncontrolled NPS has 
been for those who come into contact with drug testing, through employers, treatment 
services, the operation of motor vehicles, and the criminal justice system more generally. 
For example, SCRAs have been found to hold a particular appeal amongst US professionals 
(Perrone et al., 2013); UK professionals (Sumnall et al., 2016); UK prisoners (Brown, 2014); 
UK ex-offenders (Linnell et al 2015) and clients in treatment who are drug tested.  
(4) Media 
A fourth key driver to NPS use has been the media. Intense media scrutiny of NPS drug-
related deaths and NPS policy have led to a symbiotic relationship between press coverage, 
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policy makers and user demand for drugs (Forsyth, 2012; Measham et al., 2011b). For NPS 
at least as much as for any other drug problem, there is a sharp contrast between the lack of 
information regarding short and long term effects of use, the spiralling numbers of 
psychoactive substances available and the burgeoning easy access both to information and 
to retailers themselves through the internet. Although not unique to NPS – the early 
internet was utilised when ecstasy gained popularity with 1990s dance club cultures15 – it 
has been widely noted how pivotal the internet has been to the development of NPS 
(Forsyth, 2012; Schifano et al., 2010), with NPS being considered the first group of drugs to 
be born out of the internet age. Indeed the internet has played a multi faceted role in 
relation to the development of NPS, from the facilitation of multi media news, research data 
collection and dissemination, dark and clear net retail outlets, to online user forums and 
virtual communities (Barratt et al 2014; O’Brien et al., 2015). 
 
Conclusion: From ‘cat and mouse’ to ‘hare and hounds’ 
In answer to the question what is new about New Psychoactive Substances, it is the speed 
of innovation combined with the globalisation and virtualisation of drug markets and user 
groups that have together led to the essential ‘newness’ of the NPS phenomenon. However, 
within this innovation also lies another key feature of the NPS debate. The rapidity of NPS 
manufacturing and marketing innovations move in conjunction with the rapidity of policy 
developments. This relationship between pharmacological and policy developments was 
widely characterised in the early years as a ‘cat and mouse’ relationship (including by the 
authors elsewhere: Measham et al., 2010), with NPS chemists and entrepreneurs ready to 
respond to each new piece of legislation. Having seen several generations of NPS and NPS-
related legislation now develop, one of the authors16 has suggested that it is perhaps more 
accurate to characterise this relationship between NPS development and policy change as 
‘hare and hounds’ rather than ‘cat and mouse’ because it is the speed of policy change 
which itself is the driving force behind the faster and faster pace of NPS innovations. 
Without each set of generic controls of SCRA in the UK, for example, it is highly unlikely that 
                                                          
15 With ecstasy came the advent of ecstasy information and analysis forums and pill report sites eg. 
www.ecstasy.org. 
16 Measham, F (2014), The Unfathomable Foggyiness of Being: User motivations, market practises & policy 
implications, presentation to NPS conference, Queen Mary College, London, May 2014. 
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there would have been a further generation of SCRA development within such rapid 
succession of the previous one. 
In conclusion, we see pockets of popularity and differentiated demand for NPS around the 
world, with legislative control impacting on purity, availability, price and appeal for some 
drugs in some areas, but persistent use by some others. Although prevalence of use of NPS 
remains low by comparison with established illegal drugs in most countries, the significance 
of the rise of ‘legal highs’ relates to the rapidity of innovation in this area and also the speed 
and scale of policy responses. In contrast to established illegal drugs, control regimes have 
been quick to respond to the perceived threat, the level of which has led to innovation and 
expansion of control regimes. Therefore rather than a ‘consensus fracture’ as we have seen 
in relation to established illegal drugs and the ‘war on drugs’ (Bewley-Taylor, 2012), global 
drug prohibition regimes have indicated their capacity for innovation, adaptation and co-
operation, with a tightening of the drug policy ratchet and the blanket of prohibition being 
thrown wider (Stevens and Measham, 2014). Indeed it is in the response to criticism of 
prohibition as a creaky structure ill fitted to tackling the emergent NPS problem, that we 
have seen a reinvigoration, expansion and U-turn away from more liberal regimes with the 
introduction of the current regime of analogue, generic and ‘blanket ban’ control measures 
from 2009 onwards, resulting in a new era for both pharmacological and policy 
developments. 
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